Last $2.46 USD
Change Today +0.03 / 1.23%
Volume 44.2K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$2.43
Previous Close
$2.43
Day High
$2.47
Day Low
$2.39
52 Week High
10/2/13 - $10.56
52 Week Low
07/10/14 - $2.38
Market Cap
23.2M
Average Volume 10 Days
55.4K
EPS TTM
$-3.21
Shares Outstanding
9.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology in the United States and internationally. The company’s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melphalan hepatic delivery system that administers concentrated regional chemotherapy to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

37 Employees
Last Reported Date: 03/12/14
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Interim Co-Chief Executive Officer, Interim C...
Total Annual Compensation: $330.4K
Interim Co-Chief Executive Officer, Interim C...
Total Annual Compensation: $309.6K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $330.2K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $245.6K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $199.2K
Compensation as of Fiscal Year 2013.

delcath systems inc (DCTH) Key Developments

Delcath Systems, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Delcath Systems, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported net loss of $5,278,000 or $0.57 per basic and diluted share on total Revenue was $310,000 and loss from operations was $5,059,000 against net loss of $12,845,000 or $2.40 per basic and diluted share on total Revenue was $381,000 and loss from operations was $10,202,000 a year ago.

Delcath Systems, Inc. to Report Q1, 2014 Results on May 07, 2014

Delcath Systems, Inc. announced that they will report Q1, 2014 results on May 07, 2014

Delcath Systems, Inc., Q1 2014 Earnings Call, May 07, 2014

Delcath Systems, Inc., Q1 2014 Earnings Call, May 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $2.46 USD +0.03

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $14.71 USD +0.59
CTI BioPharma Corp $2.69 USD -0.01
Curis Inc $1.83 USD +0.14
Exact Sciences Corp $16.45 USD +0.39
Sirtex Medical Ltd A$18.49 AUD -0.27
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.8x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.